Medical Cannabis

Cannabis is a complex plant, and the impact of cannabis is growing exponentially as several potential treatment areas are covered, including research working to reveal more medical and pharmaceutical benefits, as well as a range of worldwide applications investigating the effects of cannabis. The cannabis plant contains over 100 active substances called: Cannabinoids.

Cannabinoids are active chemicals that affect receptors in the brain and human body when consumed. The two most known are Tetrahydrocannabinol (THC) and Cannabidiol (CBD).

Cannabinoids consist in three different types: those the body itself makes (Endocannabinoids), those that come from plants (Phytocannabinoids) and those that are synthesized artificially (i.e from gene modified yeast).

Cannabinoids are involved in appetite, blood pressure, blood flow to the brain, digestion, nausea, immune system, inflammation, memory, mood, movement, pain, energy balance, reproduction and stress. The discovery of the endocannabionids led researchers to the discovery of a novel physiological system, a key component of human health and self-healing ability: The Endocannabinoid System.

The Danish Pilot Programme

On 1 January 2018, medical cannabis was legalized in Denmark under a 4-year Pilot Programme that allow all Danish physicians to prescribe cannabis for medical use. The pharmaceuticals covered by the Pilot Programme are referred to as medical cannabis and may take the form of dried cannabis flowers, oils, capsules, or tablets. The Programme was approved by 9 out of 10 political parties in the Danish parliament at the time and is therefore widely supported across the political parties. 

The purpose of the Pilot Programme is to give patients a legal opportunity to test medical cannabis treatment if they have not benefited from conventional medication.